Cannara Biotech (TSE:LOVE) has released an update.
Cannara Biotech Inc. has reported a significant increase in net revenues to $19.5 million for Q3 2024, marking a 22.6% rise from the previous year, alongside a thirteenth consecutive quarter of positive Adjusted EBITDA at $2.8 million. The company, a leader in premium-grade cannabis, is making strategic investments in sales and marketing to boost distribution, market share, and prepare for further cultivation expansion.
For further insights into TSE:LOVE stock, check out TipRanks’ Stock Analysis page.
